Recent advances in nephrology have sparked a “Glomerular Revolution,” profoundly altering the medical management of rare kidney diseases. This webinar will provide a comprehensive overview of the most prevalent rare kidney diseases, including IgA nephropathy (IgAN), primary membranous nephropathy (PMN), focal segmental glomerulonephritis (FSGS) and C3 glomerulopathy (C3G). It will also review disease characteristics and shared pathophysiological drivers, with a focus on the importance of early diagnosis, biomarker use and common diagnostic challenges.
The featured speakers will discuss the unique characteristics and underlying pathophysiological overlaps that drive these conditions, focusing on the critical relevance of early diagnosis, the use of biomarkers and diagnostic challenges. While some breakthrough therapies have been approved by regulatory agencies (e.g., iptacopan, pegcetacoplan, sibeprenlimab and sparsentan), further research into combination therapies holds promise for achieving even better patient outcomes.
The webinar will further explore disease subtypes, as well as the unique challenges faced in paediatric patients, emphasizing the relevance of early diagnosis and specialized care models. Finally, the speakers will discuss the need to optimize clinical protocol design, accelerate clinical trial start-up, ensure fast recruitment and efficient patient retention, to get more and faster additional treatment options for patients to the market.
Register for this webinar to learn how biomarker-informed strategies and trial execution choices can improve decision-making in rare kidney disease.
Speakers
Jonathan Barratt, PhD, FRCP, The Mayer Professor of Renal Medicine, University of Leicester
Professor Barratt’s research concentrates on a bench-to-bedside approach to better understand the pathogenesis of IgAN. He is the lead for the IgAN Rare Disease Group within the UK National Registry of Rare Kidney Diseases and serves as a Convener of the International IgAN Network. He is the Chief Investigator for several international randomized controlled IgAN clinical trials and was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgAN Work group. Additionally, he is an Editorial Board member for Kidney International and the Journal of the American Society of Nephrology and is Co-Chair of the UK Glomerulonephritis Clinical Study Group.
Message Presenter
Claudio Hegenberger, Vice President, Scientific and Medical Affairs, Emerald Clinical
Dr. Hegenberger is an MD, specialized in Internal Medicine, with an MBA, an MSc in Pharmaceutical Science and postgraduate certifications from Georgetown University (International Business), Mount Sinai Hospital (Internal Medicine) and Harvard (Nanobiotechnology). He became an Associate Prof. of Internal Medicine in 2 main universities in Buenos Aires. He was transferred to Vienna for 3 years, and then to Madrid in 2024, where he is based now. Claudio leads the Scientific and Clinical Affairs Team and supports Business Development (BD) as the medical lead for strategy discussions, proposal development and BDMs across key therapeutic areas.
Claudio comes to Emerald Clinical after serving as VP of Medical Affairs at Pfizer Inc. He has 27 years of Pharma industry experience, including Country, Regional and Global Medical Affairs and Clinical Research roles, having extensive experience in Clinical Operations, CROs’ supervision, Pharmacovigilance, Medical Information, Safety Reporting as well as supervising Country Medical Directors, TA Medical Leads and platform lines across all therapeutic areas (IM, I&I, Vaccines, Oncology, Rare Diseases and Hospital line). He speaks English, Spanish, German and basic Portuguese fluently.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Clinical Operations Teams
- Trial Managers
- Clinical Scientists
- Clinical Research Professionals
- Clinical Outsourcing Professionals
- Medical Affairs Professionals
- Clinical Pharmacology Professionals
- Medical Directors
- Clinical Directors
What You Will Learn
Attendees will gain insight into:
- Disease Overviews: Rare renal disease overviews, including IgAN, C3G, FSGS and PMN and how newer treatments are changing care
- Pathophysiology: Molecular pathways that drive glomerular damage and implications for biomarkers and diagnosis
- Clinical Challenges: Challenges in early diagnosis, including pediatric considerations and variable prognosis
- Future Directions: Targeted and combination approaches and practical implications for clinical trial design, start-up, recruitment and retention
Xtalks Partner
Emerald Clinical
Emerald Clinical is where science, speed, and strategy come together to transform healthcare. For over 25 years, we’ve led the way in clinical research, combining global reach with deep Asia-Pacific expertise and unparalleled local insight to deliver smarter trials and stronger outcomes. With teams embedded in communities worldwide, we drive faster recruitment, deeper patient engagement, and meaningful results that move medicine forward.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account